Cobimetinib- and vemurafenib-induced granulomatous dermatitis and erythema induratum: A case report

Metastatic melanoma is an aggressive malignancy. Survival can be increased with the combination of BRAF and MEK inhibition. BRAF inhibitor-induced cutaneous toxicities can be attenuated with MEK inhibition. Here, we describe the first reported case of a patient with metastatic melanoma who developed...

Descripción completa

Detalles Bibliográficos
Autores principales: Iafolla, Marco AJ, Ramsay, Jennifer, Wismer, Judy, McWhirter, Elaine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
JCMS case report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6537058/
https://www.ncbi.nlm.nih.gov/pubmed/31205706
http://dx.doi.org/10.1177/2050313X19847358
Descripción
Sumario:Metastatic melanoma is an aggressive malignancy. Survival can be increased with the combination of BRAF and MEK inhibition. BRAF inhibitor-induced cutaneous toxicities can be attenuated with MEK inhibition. Here, we describe the first reported case of a patient with metastatic melanoma who developed granulomatous dermatitis and erythema induratum when treated with combination BRAF (vemurafenib) and MEK inhibitor (cobimetinib) therapy and discuss the clinical features and management of dermatologic side-effects secondary to BRAF +/– MEK inhibition.

Ejemplares similares